Idiopathic intracranial hypertension (IIH) affects roughly 1 in 100,000 people per year in Western countries, making it a genuinely rare condition in the general population. But that number is misleading on its own, because IIH doesn’t strike randomly. In certain groups, particularly women of childbearing age who carry extra weight, the rate jumps dramatically, to the point where “rare” no longer feels like the right word.
Overall Incidence Numbers
The baseline annual incidence of IIH in Western nations is about 0.9 per 100,000 people. To put that in perspective, if you gathered 100,000 random adults in a room, fewer than one of them would be diagnosed with IIH in a given year. That places it firmly in the “rare disease” category by most medical definitions.
Among women aged 15 to 44, the rate climbs to about 3.5 per 100,000, roughly four times the general population rate. Among women in that same age range who are obese, the incidence reaches 22 per 100,000. That’s more than 24 times the baseline rate. An earlier study looking specifically at women aged 20 to 44 who were at least 20% over their ideal weight found a rate of 19 per 100,000, which aligns closely. The pattern is consistent: the combination of female sex, younger adult age, and higher body weight transforms IIH from a rare condition into a relatively common one within that specific group.
Who Gets IIH
About 82% of new IIH diagnoses are in women, with the remaining 18% in men. The peak incidence for women occurs around age 25, while men tend to be diagnosed slightly later, with a median age of 32. The overwhelming female predominance is one of the most striking features of IIH, and it narrows further when you look only at childbearing-age women with obesity.
In children, IIH is even rarer, affecting roughly 1 in 100,000 to 150,000 kids. Children aged 12 to 17 are diagnosed at about twice the rate of younger children aged 2 to 12. Interestingly, the strong link between obesity and IIH that defines the adult form of the disease only holds up in post-pubertal adolescents. In younger, pre-pubertal children, the condition appears to have a different underlying mechanism, and the gender split is more even.
Geographic Differences
IIH rates vary significantly around the world, and the differences likely reflect regional obesity patterns. In Japan, the incidence is just 0.03 per 100,000, roughly 30 times lower than the Western average. In the Middle East, where obesity rates tend to be higher, incidence has been estimated at 2.0 to 2.2 per 100,000 in the general population, more than double the Western rate. Libya has reported a rate of 2.2 per 100,000 as well. These geographic gaps reinforce the tight connection between body weight trends and IIH frequency at a population level.
Rates Are Climbing
IIH is becoming less rare over time. As obesity rates have risen globally, so have IIH diagnoses. Recent data from the UK found 23,182 new cases over a study period, with incidence rates in obese women aged 15 to 44 reaching 22 per 100,000. That figure is substantially higher than older estimates from the 1980s and 1990s. This trend is expected to continue as long as obesity prevalence keeps rising, which means IIH will likely become an increasingly common diagnosis in the coming years, particularly in populations with higher rates of weight gain in younger women.
A Condition Often Misdiagnosed
One complication in understanding how common IIH truly is: it’s frequently overdiagnosed. A study at a major neuro-ophthalmology referral center found that nearly 40% of patients sent in with an existing IIH diagnosis didn’t actually have it. Out of 86 referred patients, 34 had been given the label incorrectly. These diagnostic errors led to unnecessary invasive procedures and, in some cases, missed the real underlying condition entirely.
The core problem is that IIH is diagnosed partly by exclusion. The modified Dandy criteria require signs of elevated pressure in the brain, a normal neurological exam, normal brain imaging (aside from a few specific findings associated with IIH itself), normal spinal fluid composition, and no other identifiable cause. Because symptoms like headache and visual changes overlap with many other conditions, and because optic nerve swelling can be mimicked by other structural variants, doctors sometimes jump to IIH when the real diagnosis is something else. This means that some portion of reported IIH cases may not be IIH at all, which could artificially inflate incidence numbers in clinical databases.
Certain Medications Increase Risk
While “idiopathic” means the cause is unknown, some cases of raised intracranial pressure are actually triggered by specific drugs. The medications most strongly linked to this effect include vitamin A derivatives (like those used for severe acne), tetracycline-class antibiotics, growth hormone therapy, and lithium. Corticosteroids carry a moderate association. A longer list of weakly associated medications includes certain contraceptives, some seizure medications, and specific immune-suppressing drugs. When a medication is responsible, the condition is technically called drug-induced intracranial hypertension rather than IIH, but the symptoms and risks are similar.
What IIH Can Do to Vision
The reason IIH matters, beyond the often severe headaches, is its potential to damage eyesight. The elevated pressure pushes on the optic nerves, causing swelling that can progressively harm vision if untreated. Most patients experience some visual symptoms, often brief episodes of dimming or blurring that last seconds. These are usually transient and reversible with treatment.
Permanent, disabling vision loss is uncommon but real. Earlier hospital-based studies reported blindness or severe visual impairment in up to 24% of patients, but those numbers came from sicker populations who were already hospitalized. More recent outpatient-based studies, which capture a broader range of severity, put the rate of severe vision loss at 6 to 14%. Catastrophic permanent vision loss occurs in roughly 1.5 to 2.6% of all IIH patients. The takeaway is that while most people with IIH retain their sight, the risk of permanent damage is significant enough that monitoring and treatment matter.
Rare Overall, Common in Specific Groups
The answer to “how rare is IIH” depends entirely on who you are. For the general population, it’s genuinely uncommon at about 1 per 100,000 per year. For a 25-year-old woman with obesity, the odds are closer to 1 in 4,500 per year, which puts it in the range of conditions most doctors will encounter regularly. If you’re a man, an older adult, or at a healthy weight, IIH is quite unlikely. If you’re a younger woman carrying significant extra weight, it’s one of the more plausible explanations for new-onset headaches with visual symptoms.